Multifunctional nanoparticle systems and methods for cancer diagnosis and combination therapy
In one aspect, compositions comprising a population of core-shell nanoparticles are described herein. In some cases, the population of core-shell nanoparticles comprises a core component and a shell component encapsulating or surrounding the core component. Additionally, one or more radiosensitizers are disposed in or dispersed throughout the core component, or an interior region of the core component. Similarly, one or more chemotherapeutic agents are disposed in or dispersed throughout the shell component, or an interior region of the shell component. Moreover, in some cases, the core component is formed from one or more biodegradable polymers. Further, in some instances, the shell component is formed from one or more stimuli responsive polymers, such as a temperature-responsive polymer and/or pH-responsive polymer.
1. A method of diagnosing and/or treating a cancer; the method comprising:
administering to a patient in need thereof a population of core-shell nanoparticles, the core-shell nanoparticles comprising:
a core component;
a shell component encapsulating the core component;
one or more radiosensitizers disposed in the core component; and
one or more chemotherapeutic agents disposed in the shell component,
wherein the core component is formed from one or more biodegradable polymers; and
wherein the shell component is formed from one or more stimuli responsive polymers that undergo a reversible phase transition in response to an external stimulus;
exposing the core-shell nanoparticles to the external stimulus;
releasing a portion of the chemotherapeutic agents in a burst release from the shell component in response to the exposure to the external stimulus; and
releasing a portion of the radiosensitizers in a sustained release from the core component in response to the exposure to the external stimulus.
2. The method of claim 1 , wherein the core component is formed from a gelatin, chitosan, alginate, starch, polysaccharide, cellulose or cellulose derivative, dextrin, dextran, fibrin, fibrinogen, fibronectin, collagen, elastin, laminin, glycosaminoglycan, hyalauronic acid, albumin, polypeptide, polylactic acid (PLA), polyglycolic acid (PGA), polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL), polyglycolide, polyanhydride, polyphosphazene, polyurethane, PLGA-chitosan copolymer, PLGA-PEG (polyethylene glycol) copolymer, or a mixture or combination thereof.
3. The method of claim 2 , wherein the core component is formed from PLGA.
4. The method of claim 1 , wherein the shell component is temperature-responsive.
5. The method of claim 1 , wherein the shell component is pH responsive.
6. The method of claim 1 , wherein the shell component is formed from a copolymer of a temperature-responsive first polymer and a pH-responsive second polymer, wherein the first and second polymers differ.
7. The method of claim 6 , wherein the shell component is formed from a poly(N-isopropylacrylamide) (PNIPAAm)-carboxymethyl chitosan (CMC) copolymer.
8. The method of claim 1 , wherein the core-shell nanoparticles further comprise a magnetic resonance imaging (MRI) contrast agent or a computed tomography (CT) contrast agent disposed in the core component and/or the shell component.
9. The method of claim 8 , wherein the contrast agent comprises superparamagnetic iron oxide (SPIO) or a lanthanide ion.
10. The method of claim 1 , wherein the composition further comprises an imaging agent disposed in the core component and/or the shell component.
11. The method of claim 10 , wherein the imaging agent comprises an organic dye, luminescent biomolecule, or a semiconductor nanocrystal.
12. The method of claim 1 , wherein the core-shell nanoparticles further comprise a targeting agent attached to the outer surface of the core-shell nanoparticles.
13. The method of claim 12 , wherein the targeting agent comprises folic acid.
14. The method of claim 1 , wherein the population of core-shell nanoparticles has an average diameter of 300 nm or less.
15. The method of claim 1 , wherein the population of core-shell nanoparticles has a negative zeta potential.
16. The method of claim 15 , wherein the negative zeta potential has an absolute value of 10 mV or more.
17. The method of claim 16 , wherein the negative zeta potential has an absolute value of 10-40 mV.
18. The method of claim 1 , wherein releasing the portion of the chemotherapeutic agents and releasing the portion of the radiosensitizers begin simultaneously.
19. A method of diagnosing and/or treating a cancer, the method comprising:
administering to a patient in need thereof a population of core-shell nanoparticles, the core-shell nanoparticles comprising:
a core component;
a shell component encapsulating the core component;
one or more radiosensitizers disposed in the core component; and
one or more chemotherapeutic agents disposed in the shell component,
wherein the core component is formed from one or more biodegradable polymers; and
wherein the shell component is formed from one or more stimuli responsive polymers that undergo a reversible phase transition in response to an external stimulus;
exposing the core-shell nanoparticles to the external stimulus,
releasing a portion of the chemotherapeutic agents in a burst release from the shell component in response to the exposure to the external stimulus; and
releasing a portion of the radiosensitizers in a sustained release from the core component in response to the exposure to the external stimulus,
wherein the composition is administered to the patient as an aerosol or an inhalant via a nebulizer and wherein the cancer is lung cancer.
20. The method of claim 1 , wherein the radiosensitizers, chemotherapeutic agents, or both are releasable from the core-shell nanoparticles in the presence of the external stimulus and are unreleasable in the absence of the external stimulus.
21. The method of claim 1 , wherein the burst release corresponds to a release of at least 20% of the chemotherapeutic agents within a period of 2 days or less.
22. The method of claim 1 , wherein the sustained release corresponds to a release of less than 20% of the radiosensitizers within 2 days.
23. The method of claim 1 , wherein the external stimuli comprises radiation therapy.
24. The method of claim 23 , wherein the radiation therapy comprises external beam radiation therapy, brachytherapy, or systemic radioisotope therapy.
25. The method of claim 1 , wherein the external stimuli comprises an applied external magnetic field.
26. The method of claim 5 , wherein the pH-responsive shell material is a pH-responsive polymer.